Stevanato Group Opens Technology Excellence Center in Boston

Stevanato Group, a producer of pharmaceutical glass containers and provider of integrated capabilities for drug delivery systems, has officially inaugurated its Technology Excellence Center (TEC) in Boston, Massachusetts.

The new center provides a full-service approach to support biopharma companies along the drug development journey, from early phase development to commercialization, helping them overcome container-closure system hurdles. With growing demand for biologic therapies in the US, the Boston-based laboratory is well positioned to offer integrated development and analytical services to support local biopharma companies in their drug development journey. 

“We built on our analytical laboratory experience in our headquarters in Italy, to create the first Technology Excellence Center in Boston. We took this step also in the U.S. thanks to the positive feedback received from our customers. They confirmed our capability to work with them as true partners, integrating both our and their technical teams and analytical competencies. As a result, they benefited from an optimized drug development process, reduced time-to-market, increased flexibility, and reduced total cost of ownership. U.S. TEC represents a unique business model that we wish to replicate in other regions,” said Franco Stevanato, CEO.

"We are excited to open the doors of our new Technology Excellence Center right here in Boston at the heart of the biotech community. Given its location, the TechnologyExcellence Center can easily integrate with the value chain of U.S. customers, by partnering with them at an early stage. We can anticipate challenges and present viable, robust solutions that save development time and resources,” commented Paolo Patri, Stevanato Group chief technology officer.

Leveraging the Group’s knowledge in material science of glass, plastics, and rubber, the U.S. TEC will cover one of the most binding decisions for biopharma industry players: how to select the primary container for a biopharmaceutical product

“Massachusetts continues to attract life sciences companies from across the globe, who come here to access our leading academic and medical centers, diverse talent, a supportive government, and a robust startup community,” said Robert K. Coughlin, president & CEO, MassBio. “We are thrilled to welcome Stevanato Group to the #1 life sciences cluster in the world and are confident their Technology Excellence Center will support the diverse needs of biopharma companies as they seek to bring new therapies to patients.”

Stevanato Group has more than 70 years of experience in glass primary container manufacturing, with extensive background knowledge of glass primary packaging design and technology. Since 2014, its interdisciplinary team of technicians and scientists in Italy has been building upon this knowledge with a wide range of testing, from container performance to chemical analysis, container interaction, and surface characterization. 

The company has also strengthened its offerings at the U.S. TEC through a network of strategic partnerships with container closure integrity (CCI) testing provider , Pfeiffer Vacuum,  Extractables & Leachables testing with Nelson Labs, and small-scale fill & finish with COLANAR.